Sharekhan

Supriya Lifescience Ltd

Wed 21/05/2025,15:58:37 NSE: SUPRIYA

₹ 715.70 0.90 (0.13%)
BUY NOW Buy Supriya Lifescience Ltd Stock

Open Free Demat and Trading account in 15 minutes

Home Stock Supriya Lifescience Ltd

Wed 21/05/2025,16:1:0

Supriya Lifescience Ltd

Wed 21/05/2025,15:58:37 | NSE : SUPRIYA

₹ 715.700.90 (0.13%)

Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.

Market Data

Essential tool: analyze, trade, manage, decide.

Open

₹ 720.00

Previous Close

₹ 714.80

Volume

154193

Mkt Cap ( Rs. Cr)

₹5760.15

High

₹ 723.95

Low

₹ 705.25

52 Week High

₹ 842.00

52 Week Low

₹ 330.00

Book Value Per Share

₹ 112.56

Dividend Yield

0.00

Face Value

₹ 2.00

What’s Your Call?

Collective community sentiment on Supriya Lifescience Ltd

Your Vote -

Buy

65.91%

Hold

5.68%

Sell

28.41%

65.91%

88 users have voted

Market Depth

How many stocks are available to buy or sell and at what prices.

Buy Order Quantity

0%

Sell Order Quantity

100%

Bid Price

Qty

0.00

0

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

0

Bid Price

Qty

715.70

11

0.00

0

0.00

0

0.00

0

0.00

0

Bid Total

11

Option Chain

Analyzes market sentiment, predicts Supriya Lifescience Ltd' movement.

NO_RECORD_FOUND

News

Media spotlight triggers stock stock attention, sentiment.

  • Supriya Lifescience - Board Meeting Intimation for Audited Financial Results Of The Company For The Quarter And Year Ended Ma

    20 May 2025, 5:16PM Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 27/05/2025 ,inter alia, to consider

  • Supriya Lifescience - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A

    28 Apr 2025, 12:31PM <b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border='1px'><tr> <td><b>Sr. No.</b></td

  • Supriya Lifescience - Shareholders meeting

    24 Apr 2025, 5:10PM Supriya Lifescience Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange reg

  • Supriya Lifescience - Shareholder Meeting / Postal Ballot-Scrutinizer\s Report

    24 Apr 2025, 5:13PM The Scrutinizers' report & Voting Results for the Postal ballot conducted by the Company is attached herewith.

  • Supriya Lifescience - Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot

    24 Apr 2025, 5:11PM The Voting Results and Scrutinizers' Report for the Postal Ballot conducted by the Company is attached herewith.

  • Supriya Lifescience has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2025

    17 Apr 2025, 5:20PM As of March 2025, 68.30% is owned by Indian Promoters and 31.70% by Public. <p align=justify> Institutional holds 11.45% (Insurance Companies 1.70%) a

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    15 Apr 2025, 5:27PM Supriya Lifescience Limited has informed the Exchange about Schedule of meet

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    15 Apr 2025, 5:28PM Enclosed herewith details of Analyst/Institutional Investor Meeting.

  • Supriya Lifescience - Certificate under SEBI (Depositories and Participants) Regulations, 2018

    11 Apr 2025, 4:58PM Company has informed the exchange about certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended March 31, 2025

  • Supriya Lifescience - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

    11 Apr 2025, 4:57PM Company has informed exchanges about certificate under Regulation 74(5) of SEBI (DP) Regulations, 2018 for the quarter ended March 31, 2025.

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    1 Apr 2025, 5:16PM Enclosed herewith details of Analyst/Institutional Investor Meetings.

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    1 Apr 2025, 5:17PM Enclosed herewith details of Analyst/Institutional Investor Meetings.

  • Supriya Lifescience - Trading Window-XBRL

    26 Mar 2025, 5:30PM Supriya Lifescience Limited has informed the Exchange about Closure of Trading Window

  • Supriya Lifescience - Trading Window

    26 Mar 2025, 5:26PM Supriya Lifescience Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulatio

  • Supriya Lifescience - Copy of Newspaper Publication

    25 Mar 2025, 4:38PM Supriya Lifescience Limited has informed the Exchange about Copy of Newspaper Publication for Postal Ballot

  • Supriya Lifescience - Notice Of Shareholders Meetings-XBRL

    24 Mar 2025, 4:29PM Supriya Lifescience Limited has informed the Exchange about Notice of Shareholders Meeting for Postal Ballot

  • Supriya Lifescience - Shareholders meeting

    24 Mar 2025, 4:27PM Supriya Lifescience Limited has informed the Exchange regarding Notice of Postal Ballot

  • Supriya Lifescience - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot

    24 Mar 2025, 4:24PM Please find attached Postal Ballot Notice of Supriya Lifesciences Limited

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    17 Mar 2025, 5:49PM Pursuant to Regulation 30 of SEBI LODR Regulations, 2015, the details of the Analyst/Investor Meetings to be attended by the Company are as enclosed h

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    17 Mar 2025, 5:46PM Pursuant to Regulation 30 of SEBI (LODR) Regulations, 2015, the details of the Analyst/ Investor Meetings to be attended by the Company are enclosed h

  • Supriya Lifescience - General Updates

    10 Mar 2025, 3:49PM Details Of Key Managerial Personnel Under Regulation 30(5) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

  • Supriya Lifescience - Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer Agent

    10 Mar 2025, 3:41PM SUPRIYA LIFESCIENCE LIMITED has informed the Exchange about Change in Directors/ Key Managerial Personnel/ Auditor/ Compliance Officer/ Share Transfer

  • Supriya Lifescience - Appointment of Company Secretary and Compliance Officer

    10 Mar 2025, 3:21PM The Board of Directors at their meeting held on March 10, 2025, inter alia considered and approved:\r\n1. Appointment of Ms. Prachi Sathe bearing Memb

  • Supriya Lifescience - Appointment

    10 Mar 2025, 3:21PM Supriya Lifescience Limited has informed the Exchange regarding Appointment of Ms PrachiSathe as Company Secretary & Compliance Officer of the company

  • Supriya Lifescience - Outcome of Board Meeting

    10 Mar 2025, 12:28PM Outcome of Board Meeting held to consider appointment of Company Secretary and Compliance Officer of the Company.

  • Supriya Lifescience - Details Of Key Managerial Personnel Under Regulation 30(5) Of SEBI (Listing Obligations And Disclosure

    10 Mar 2025, 3:46PM Please find attached the details of KMP

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Change in Management

    10 Mar 2025, 3:25PM The Board of Directors at their meeting held on March 10, 2025, inter alia have considered and approved the \r\n1.appointment of Ms. Prachi Sathe bear

  • Supriya Lifescience - Board Meeting Outcome for Outcome Of Board Meeting Held To Consider Appointment Of Company Secretary An

    10 Mar 2025, 12:29PM With reference to above subject matter and pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we w

  • Supriya Lifescience - Board Meeting Intimation

    5 Mar 2025, 4:20PM SUPRIYA LIFESCIENCE LIMITED has informed the Exchange about Board Meeting to be held on 10-Mar-2025 to consider Other business.

  • Supriya Lifescience - Board Meeting Intimation

    5 Mar 2025, 4:10PM SUPRIYA LIFESCIENCE LIMITED has informed the Exchange about Board Meeting to be held on 10-Mar-2025 to consider Other business.

  • Supriya Lifescience - Board Meeting Intimation for Appointment Of Company Secretary And Compliance Officer Of The Company

    5 Mar 2025, 4:02PM Supriya Lifescience Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/03/2025 ,inter alia, to consider

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    26 Feb 2025, 4:45PM Supriya Lifescience Limited has informed the Exchange about Schedule of meet

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    26 Feb 2025, 4:43PM Supriya Lifescience Limited has informed the Exchange about Schedule of meet

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    26 Feb 2025, 4:40PM Supriya Lifescience Limited has informed the Exchange about Schedule of meet

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    26 Feb 2025, 4:26PM Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    26 Feb 2025, 4:23PM Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    26 Feb 2025, 4:20PM Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015

  • Supriya Lifescience - Analysts/Institutional Investor Meet/Con. Call Updates

    25 Feb 2025, 1:29PM Supriya Lifescience Limited has informed the Exchange about Schedule of meet

  • Supriya Lifescience - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

    25 Feb 2025, 1:11PM Schedule of Analyst / Institutional Investor meetings under the SEBI (Listing Obligations and Disclosure Requirements), Regulations 2015

  • Supriya Life

    29 Sep 2022 , 11:11AM The company gets European drug body's approval for antihistamine drug. Diphenhydramine Hydrochloride is an antihistamine that reduces the effects of natural chemical histamine in the body. It is used to treat sneezing, runny nose, watery eyes, hives, skin rash, itching, and other cold or allergy symptoms – Positive read through for the stock.

  • Supriya Life gets European drug body's approval for antihistamine drug

    29 Sep 2022 , 9:41AM EDQM grants Certification of Suitability for Diphenhydramine Hydrochloride, API in AntiHistamine therapy
Load More
Show Less

Key fundamentals

Evaluate the intrinsic value of Supriya Lifescience Ltd stock 

Name March-24 March-23 March-22 March-21 March-20
Assets 815.368 716.083 636.983 335.993 232.0988
Liabilities 815.368 716.083 636.983 335.993 232.0988
Equity 16.097 16.097 16.097 14.637 14.6367
Gross Profit 172.976 128.897 213.984 167.295 98.6408
Net Profit 119.114 89.857 151.81 123.593 72.1597
Cash From Operating Activities 113.307 66.187 48.801 78.905 116.6659
NPM(%) 20.88 19.49 28.64 32.07 23.15
Revenue 570.37 460.938 530.049 385.366 311.6443
Expenses 397.394 332.041 316.065 218.071 213.0035
ROE(%) 13.14 9.91 16.75 13.64 7.96

Shareholding Pattern

Corporate Action

XD-Date Dividend-Amount Dividend-% Dividend Yield(%GE) Price on that day
20 Sep 2024 0.8 40 0 363.1
15 Sep 2023 0.6 30 0 256.65
01 Sep 2022 0.6 30 0 378.15

Peers

Other companies within the same industry or sector that are comparable to Supriya Lifescience Ltd

Company Price Price (% change) pe(x) EV/EBITDA(x) ROE(%) ROCE(%)
Albert David Ltd 810.15 -0.84 26.88 407.87 301.39 0.62
Lotus Eye Hospital and Institute Ltd 74.06 0.78 308.58 1486.21 14.01 0.68
Vaishali Pharma Ltd 12.85 -1.15 428.33 766.05 2.76 0.00
Astec Lifesciences Ltd 701.25 -1.59 0.00 1401.37 -687.11 0.00

Company Info

The Company was incorporated as `Supriya Lifescience Limited' pursuant to a certificate of incorporation dated March 26, 2008 issued by the Registrar of Companies, Maharashtra at Mumbai ("RoC"), upon the conversion of `M/s Supriya Chemicals', a partnership firm, into a public limited company, in accordance with the provisions of Part IX of the Companies Act, 1956. the Company commenced operations pursuant to a certificate for commencement of business dated April 1, 2008 issued by the RoC.Major events and milestones of the Company :2008- Incorporation of the Company upon its conversion from a partnership firm to a public limited company2009- Started production of Ketamine Hydrochloride2010- CEP (Certificate of Sustainability) granted for Chlorphenamine Maleate2011- IDL granted for Chlorphenamine Maleate2013- COFEPRIS and KFDA approval granted2014- USFDA approval granted- IDL granted for Brompheniramine Maleate2015- EUGMP and EDQM approval granted2017- CEP (Certificate of Sustainability) granted for Pheniramine Maleate- Second time USFDA approval granted2018- CEP (Certificate of Sustainability) granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride2020- Third time USFDA approval2021- CEP (Certificate of Suitability) granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate- NMPA approval granted- Health Canada approval 2022 -Supriya Lifescience Limited has informed the Exchange regarding 'Intimation Regarding Captive Solar Project Agreement Signed with Enrich Energy Pvt. Ltd'. 2024 -"Supriya Lifescience Ltd Inaugurates State-of-the-Art Module E Production Block at Lote Parshuram, Maharashtra". --Supriya Lifescience inaugurates Rs 125 crore API production block at Lote Parshuram site.

The Company was incorporated as `Supriya Lifescience Limited' pursuant to a certificate of incorporation dated March 26, 2008 issued by the Registrar of Companies, Maharashtra at Mumbai ("RoC"), upon the conversion of `M/s Supriya Chemicals', a partnership firm, into a public limited company, in accordance with the provisions of Part IX of the Companies Act, 1956. the Company commenced operations pursuant to a certificate for commencement of business dated April 1, 2008 issued by the RoC.Major events and milestones of the Company :2008- Incorporation of the Company upon its conversion from a partnership firm to a public limited company2009- Started production of Ketamine Hydrochloride2010- CEP (Certificate of Sustainability) granted for Chlorphenamine Maleate2011- IDL granted for Chlorphenamine Maleate2013- COFEPRIS and KFDA approval granted2014- USFDA approval granted- IDL granted for Brompheniramine Maleate2015- EUGMP and EDQM approval granted2017- CEP (Certificate of Sustainability) granted for Pheniramine Maleate- Second time USFDA approval granted2018- CEP (Certificate of Sustainability) granted for Brompheniramine Maleate, Mepyramine Maleate & Ketamine Hydrochloride2020- Third time USFDA approval2021- CEP (Certificate of Suitability) granted for Pentoxifylline, Esketamine Hydrochloride and Salbutamol Sulphate- NMPA approval granted- Health Canada approval 2022 -Supriya Lifescience Limited has informed the Exchange regarding 'Intimation Regarding Captive Solar Project Agreement Signed with Enrich Energy Pvt. Ltd'. 2024 -"Supriya Lifescience Ltd Inaugurates State-of-the-Art Module E Production Block at Lote Parshuram, Maharashtra". --Supriya Lifescience inaugurates Rs 125 crore API production block at Lote Parshuram site.

Read More

Parent Organisation

Supriya Lifescience Ltd.

Founded

26/03/2008

Managing Director

NSE Symbol

SUPRIYAEQ

FAQ

The current price of Supriya Lifescience Ltd is ₹ 715.70.

The 52-week high for Supriya Lifescience Ltd is ₹ 723.95 and the 52-week low is ₹ 705.25.

The market capitalization of Supriya Lifescience Ltd is currently ₹ 5760.15. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.

To buy Supriya Lifescience Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.

To invest in Supriya Lifescience Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Supriya Lifescience Ltd shares.

The CEO of Supriya Lifescience Ltd is , who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.

OPEN FREE* DEMAT ACCOUNT